Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
26 hedge funds and large institutions have $82.3M invested in Bellerophon Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
161% more capital invested
Capital invested by funds: $31.5M → $82.3M (+$50.8M)
53% more funds holding
Funds holding: 17 → 26 (+9)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
+$416K |
| 2 |
Renaissance Technologies
New York
|
+$327K |
| 3 |
Bank of New York Mellon
New York
|
+$310K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$226K |
| 5 |
TI
Telemetry Investments
New York
|
+$139K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$453K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$28K |
| 3 |
Millennium Management
New York
|
-$18K |
| 4 |
LPL Financial
San Diego,
California
|
-$3.49K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$393 |
BLPH Hedge Fund Activity: Q4 2017 in Review
26 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q4 2017, worth a combined $82.3M — up 161% from $31.5M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new BLPH positions and 3 closed out — a net gain of 9 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was EAM Investors, opening a new position worth an estimated $416K. The largest seller was Fidelity Investments, cutting an estimated $453K.
- 26 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q4 2017, up from 17 in Q3 2017.
- Funds reported $82.3M of Bellerophon Therapeutics, Inc. stock for Q4 2017, up 161% quarter-over-quarter.
- 12 funds opened new Bellerophon Therapeutics, Inc. positions in Q4 2017 and 3 closed out, a net change of +9 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q4 2017 was EAM Investors, an estimated $416K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q4 2017 was Fidelity Investments, an estimated $453K sold.
Based on aggregated 13F filings for Q4 2017.